NasdaqGM:FLY
NasdaqGM:FLYAerospace & Defense

Does Firefly Aerospace’s Contract Win Signal a Turnaround for the Stock in 2025?

Wondering if Firefly Aerospace is a bargain or overpriced right now? You are not alone, as curiosity around the stock's real value is picking up steam. After a rocky start to the year, the stock surged 16.3% in the last week. This comes after a steep 62.0% slide year-to-date and a recent 22.5% drop over the past month. This comeback follows reports that Firefly recently secured additional contracts in the commercial launch sector, alongside growing investor attention as the...
NYSE:SHCO
NYSE:SHCOHospitality

Assessing Soho House & Co (SHCO) Valuation After a Strong Year of Share Price Growth

Soho House & Co (SHCO) stock has gained renewed attention lately, as investors look at its long-term performance and recent momentum. Shares have climbed 15% over the past 3 months and are up 72% in the past year. See our latest analysis for Soho House & Co. Momentum looks to be building for Soho House & Co, with the share price showing strong upward movement over the past year. After some recent volatility, the stock is still trading near recent highs, and its 1-year total shareholder return...
NasdaqCM:CURI
NasdaqCM:CURIEntertainment

A Look at CuriosityStream (CURI) Valuation Following AI Licensing Growth and New Dividend Initiatives

CuriosityStream (CURI) caught investor attention this week after reporting sizeable revenue growth and revealing a strategic push into AI video training data licensing. The company’s new focus aims to unlock higher-margin and steadier revenue streams. See our latest analysis for CuriosityStream. Momentum has clearly picked up for CuriosityStream this year, with a 16% jump in share price over the past week and a staggering 189% year-to-date share price return. This sharp rebound follows upbeat...
NasdaqGS:TCBK
NasdaqGS:TCBKBanks

How Analyst Upgrades and a Dividend Hike at TriCo Bancshares (TCBK) Have Changed Its Investment Story

TriCo Bancshares recently received an average "Moderate Buy" recommendation from seven brokerages, with several analysts upgrading their ratings and increasing targets, and announced a quarterly dividend increase to US$0.36 per share. This combination of analyst optimism and a higher dividend payout signals growing confidence in the company’s direction and outlook. We'll explore how the dividend hike reflects management's confidence and what it could mean for TriCo Bancshares' investment...
NasdaqGS:IBOC
NasdaqGS:IBOCBanks

How Sustained Net Income Growth and No Buybacks This Quarter Could Shape International Bancshares' (IBOC) Story

International Bancshares Corporation recently reported third quarter and nine-month earnings, with net interest income reaching US$172.23 million and net income rising to US$108.38 million for the quarter ending September 30, 2025. Consistent growth in both quarterly and year-to-date earnings per share underscored improving profitability, while no shares were repurchased during the latest buyback tranche. We'll explore how the sustained year-over-year growth in net income shapes...
NasdaqGM:CVAC
NasdaqGM:CVACBiotechs

Does CureVac’s 108% Rally Signal a Smarter Opportunity After mRNA Breakthrough News?

Ever wondered whether CureVac's stock is a hidden gem or a value trap? You're not alone as many investors are taking a closer look after a wild ride. Despite a turbulent three-year stretch, CureVac shares are up an eye-popping 107.9% in the past year, with a year-to-date gain of 53% sparking new optimism and debate about its outlook. Recent attention around CureVac has centered on developments in its mRNA vaccine research as well as fresh updates on ongoing clinical trials. These...
NasdaqGS:SBRA
NasdaqGS:SBRAHealth Care REITs

Evaluating Sabra Health Care REIT (SBRA) Valuation Following Recent 6% Share Price Gain

Sabra Health Care REIT (SBRA) has recently attracted attention as investors dig into its performance over the past month, with the stock advancing almost 6%. This steady upward movement has prompted some investors to revisit their expectations for the real estate investment trust. See our latest analysis for Sabra Health Care REIT. After climbing nearly 6% over the past month, Sabra Health Care REIT is showing signs of renewed momentum, building on a 9% share price return year-to-date and an...
NasdaqCM:PLSE
NasdaqCM:PLSEMedical Equipment

Pulse Biosciences (PLSE): Assessing Valuation Following Modest Share Rebound and Recent Slowdown

Pulse Biosciences (PLSE) shares have edged up slightly in recent trading, gaining just under 2% following a stretch of losses this month. The move comes as investors reassess the company’s outlook in light of continued volatility in the healthcare sector. See our latest analysis for Pulse Biosciences. This latest rebound offers a bit of relief for Pulse Biosciences after a tough run that saw the share price slump over the past month. The company’s three-year total shareholder return is still...
NYSE:VRTS
NYSE:VRTSCapital Markets

Virtus Investment Partners (VRTS): Evaluating the Value Opportunity After Recent Share Price Weakness

Virtus Investment Partners (VRTS) shares have come under pressure over the past month, declining 16%. Investors are taking a closer look at the stock’s trajectory and considering potential catalysts that could shape its direction. See our latest analysis for Virtus Investment Partners. After a tough 30-day stretch for Virtus Investment Partners, with a share price return of -15.5%, the year-to-date slide has extended to -26.1%. Momentum looks decidedly challenged, and the past year’s total...
NYSE:BORR
NYSE:BORREnergy Services

Is Surging Rig Utilization and Contract Wins Altering the Investment Case for Borr Drilling (BORR)?

Borr Drilling Limited recently reported its third quarter 2025 results, posting US$277.1 million in revenue and US$27.8 million in net income, both increasing significantly from the same period last year. An unusually high rig utilization rate and continued contract wins, particularly in markets like Saudi Arabia and Mexico, highlight robust operational momentum for the company. We'll examine how Borr Drilling's increased rig activity and new contract commitments could affect the company's...
NasdaqGS:VRSN
NasdaqGS:VRSNIT

Does Ongoing Insider Selling at VeriSign (VRSN) Signal Shifts in Management’s Long-Term Conviction?

On November 13, 2025, VeriSign's Executive Chairman, President, and CEO, D Bidzos, sold 9,000 shares of the company according to an SEC filing. This sale adds to a pattern of insider selling, as the CEO has sold a total of 108,000 shares over the past year without making any purchases, highlighting ongoing executive share sales. We'll now examine how recent insider selling by VeriSign's CEO may influence the company's investment narrative and investor confidence. Find companies with...
NYSE:HAE
NYSE:HAEMedical Equipment

Is Haemonetics’ (HAE) Shift to Profitability and Buybacks a New Capital Allocation Play?

Haemonetics Corporation recently reported second quarter results, showing a year-over-year sales decline to US$327.32 million but an increase in net income to US$38.68 million and earnings per share to US$0.81; the company also completed a buyback of 1,430,579 shares, around 2.97% of its outstanding stock, for US$75 million. This combination of higher earnings and reduced share count highlights management's focus on profitability and capital returns despite softer top-line performance. We’ll...
NasdaqGS:BBIO
NasdaqGS:BBIOBiotechs

BridgeBio Pharma Soars 135% as FDA Milestones Spark Valuation Debate for 2025

Ever wondered if BridgeBio Pharma's wild ride means it's a smart buy or just hyped up? This article takes a closer look at the real value, so you know what you’re really getting into. The stock has soared with a jaw-dropping 135.4% gain so far this year and is up an incredible 179.9% over the past year, making many investors take a closer look. Headlines have focused on BridgeBio's clinical trial successes and fresh partnerships, fueling optimism and driving the stock...
NasdaqGS:HWC
NasdaqGS:HWCBanks

Did Hancock Whitney's (HWC) Strong Q3 Earnings and Buyback Signal a Shift in Its Growth Story?

In November 2025, Hancock Whitney reported third-quarter earnings that exceeded expectations, fueled by increases in both non-interest and net interest income, and announced plans to repurchase an additional 443,700 shares. The company provided forward guidance highlighting anticipated growth in loan balances, deposit growth, modestly rising net interest income, and further margin expansion, reflecting confidence in its ongoing strategy. Hancock Whitney’s management also outlined a...
NYSE:ARCO
NYSE:ARCOHospitality

Arcos Dorados (NYSE:ARCO): Assessing Valuation After Recent Modest Share Price Bump

Arcos Dorados Holdings (NYSE:ARCO) has been drawing attention with its recent stock movement and underlying performance. Investors are looking into how its fundamentals and recent trends might shape sentiment, particularly over the past month. See our latest analysis for Arcos Dorados Holdings. While Arcos Dorados Holdings has seen a modest bump lately, with a 1-month share price return of just over 5%, the bigger picture shows momentum has yet to turn the tide. Over the past year, total...